Patient-centred approaches for the management of unpleasant symptoms in kidney disease.
Kalantar-Zadeh K, Lockwood MB, Rhee CM, Tantisattamo E, Andreoli S, Balducci A, Laffin P, Harris T, Knight R, Kumaraswami L, Liakopoulos V, Lui SF, Kumar S, Ng M, Saadi G, Ulasi I, Tong A, Li PK.
Nat Rev Nephrol. 2022 Mar;18(3):185-198. doi: 10.1038/s41581-021-00518-z. Epub 2022 Jan 3.
Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling.
Nigam SK, Bush KT.
Nat Rev Nephrol. 2019 May;15(5):301-316. doi: 10.1038/s41581-019-0111-1.
Protein metabolism in uraemia.
Richards P.
Nephron. 1975;14(2):134-52. doi: 10.1159/000180444.
Carbohydrate metabolism in uraemia.
Rigalleau V, Gin H.
Curr Opin Clin Nutr Metab Care. 2005 Jul;8(4):463-9. doi: 10.1097/01.mco.0000172590.32564.b9.
Uraemic sarcopenia: aetiology and implications.
Fahal IH.
Nephrol Dial Transplant. 2014 Sep;29(9):1655-65. doi: 10.1093/ndt/gft070. Epub 2013 Apr 25.
Effects of renal substitutive programs on amino acid patterns in chronic uremia.
Scolari MP, Stefoni S, Mosconi G, Colì L, Feliciangeli G, Baldrati L, Buscaroli A, Prandini R, Bonomini V.
Kidney Int Suppl. 1983 Dec;16:S77-80.
Hypertension in end-stage renal disease.
Appleby C, Foley RN.
Minerva Urol Nefrol. 2002 Mar;54(1):37-43.
Disorders of left ventricular structure and function in chronic uremia: how often, why and what to do with it?
Dyadyk OI, Bagriy AE, Yarovaya NF.
Eur J Heart Fail. 1999 Dec;1(4):327-36. doi: 10.1016/s1388-9842(99)00057-4.
Myeloid leukocytes' diverse effects on cardiovascular and systemic inflammation in chronic kidney disease.
Hof A, Geißen S, Singgih K, Mollenhauer M, Winkels H, Benzing T, Baldus S, Hoyer FF.
Basic Res Cardiol. 2022 Jul 27;117(1):38. doi: 10.1007/s00395-022-00945-4.
Modulation of protein kinetics in chronic renal failure.
Guarnieri G, Toigo G, Situlin R, Ciocchi B, Biolo G.
Miner Electrolyte Metab. 1997;23(3-6):214-7.
